Valuation: Ardelyx, Inc.

Market Cap 1.37B 1.2B 1.11B 1.04B 1.95B 129B 1.99B 13.32B 5.15B 63.92B 5.15B 5.04B 222B P/E 2026 *
-116x
P/E 2027 * 12x
Enterprise Value 1.37B 1.2B 1.11B 1.04B 1.95B 129B 1.99B 13.32B 5.15B 63.92B 5.15B 5.04B 222B EV / Sales 2026 *
2.52x
EV / Sales 2027 * 1.85x
Free-Float
96.73%
Yield 2026 *
-
Yield 2027 * -
1 day-8.42%
1 week-8.26%
Current month-8.11%
1 month-10.05%
3 months+1.28%
6 months-3.31%
Current year-4.80%
1 week 5.45
Extreme 5.45
6.47
1 month 5.31
Extreme 5.31
6.47
Current year 5.1
Extreme 5.105
8.4
1 year 3.74
Extreme 3.74
8.4
3 years 3.16
Extreme 3.16
10.13
5 years 0.49
Extreme 0.4902
10.13
10 years 0.49
Extreme 0.4902
16.3
Manager TitleAgeSince
Chief Executive Officer 61 2009-02-28
Director of Finance/CFO 55 2025-11-03
Chief Tech/Sci/R&D Officer 50 2026-03-31
Director TitleAgeSince
Director/Board Member 61 2009-02-28
Chairman 60 2014-02-28
Director/Board Member 59 2014-02-28
Date Insider Type Main position Quantity % Market Cap.
06-17Fiscal year

Executive/Senior Manager

143,898 0.0583%
06-15Free

Director

66,170 0.0268%
06-15Free

Director

66,170 0.0268%
Change 5-day change 1-year change 3-year change Capi.($)
-8.42%-8.26%+50.41%+65.18% 1.37B
+0.33%+1.37%+63.66%+126.38% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-13.83% 23.07B
-1.04%+7.91%+3.91%+417.68% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+186.30% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average -0.74%+3.47%+43.19%+123.32% 22.77B
Weighted average by Cap. +0.21%+5.05%+48.51%+122.31%

Financials

2026 *2027 *
Net sales 544M 477M 439M 411M 771M 51.29B 787M 5.28B 2.04B 25.35B 2.04B 2B 87.89B 740M 648M 598M 560M 1.05B 69.76B 1.07B 7.18B 2.78B 34.48B 2.78B 2.72B 120B
Net income -11.62M -10.19M -9.39M -8.79M -16.49M -1.1B -16.83M -113M -43.68M -542M -43.64M -42.68M -1.88B 121M 106M 97.39M 91.18M 171M 11.37B 175M 1.17B 453M 5.62B 452M 443M 19.48B
Net Debt - -
Logo Ardelyx, Inc.
Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical need. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. NHE3 is an antiporter expressed on the apical surface of the small and large intestines. Tenapanor is a minimally absorbed, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation. Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. In addition to commercializing IBSRELA and XPHOZAH, it is also developing a next-generation NHE3 inhibitor.
Employees
489
Date Price Change Volume
26-06-26 US$5.550 -8.42% 17,524,272
26-06-25 US$6.060 -2.10% 2,109,279
26-06-24 US$6.190 +0.16% 2,892,716
26-06-23 US$6.180 -2.98% 3,087,210
26-06-22 US$6.370 +5.29% 4,905,851
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
5.550USD
Average target price
16.30USD
Spread / Average Target
+193.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARDX Stock